TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) today announced the award of grants totaling $1.9 million by the National Institutes of Health (NIH). The proceeds, to be disbursed over two years, were awarded to support the development and initiation of clinical testing of a novel antibody-drug conjugate (ADC) and vaccine immunotherapies that target prostate-specific membrane antigen (PSMA), a molecular marker found on prostate cancer cells. Progenics also announced the publication of two scientific articles that describe positive preclinical findings from these programs.
